WO2012158614A2 - Implantable materials having engineered surfaces and method of making same - Google Patents

Implantable materials having engineered surfaces and method of making same Download PDF

Info

Publication number
WO2012158614A2
WO2012158614A2 PCT/US2012/037776 US2012037776W WO2012158614A2 WO 2012158614 A2 WO2012158614 A2 WO 2012158614A2 US 2012037776 W US2012037776 W US 2012037776W WO 2012158614 A2 WO2012158614 A2 WO 2012158614A2
Authority
WO
WIPO (PCT)
Prior art keywords
implantable
layer
physiologically functional
biocompatible
functional features
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/037776
Other languages
English (en)
French (fr)
Other versions
WO2012158614A3 (en
Inventor
Julio C. Palmaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palmaz Scientific Inc
Original Assignee
Palmaz Scientific Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palmaz Scientific Inc filed Critical Palmaz Scientific Inc
Priority to AU2012255972A priority Critical patent/AU2012255972B2/en
Priority to CN201280031581.4A priority patent/CN103619364A/zh
Priority to MX2013013139A priority patent/MX2013013139A/es
Priority to EP12786428.8A priority patent/EP2707044B1/en
Priority to JP2014510536A priority patent/JP2014514127A/ja
Priority to CA2835844A priority patent/CA2835844C/en
Publication of WO2012158614A2 publication Critical patent/WO2012158614A2/en
Publication of WO2012158614A3 publication Critical patent/WO2012158614A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077Special surfaces of prostheses, e.g. for improving ingrowth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C23COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23CCOATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C14/00Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
    • C23C14/04Coating on selected surface areas, e.g. using masks
    • C23C14/042Coating on selected surface areas, e.g. using masks using masks
    • CCHEMISTRY; METALLURGY
    • C23COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23CCOATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C14/00Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
    • C23C14/22Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
    • C23C14/24Vacuum evaporation
    • CCHEMISTRY; METALLURGY
    • C23COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23CCOATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C14/00Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
    • C23C14/58After-treatment
    • C23C14/5873Removal of material
    • GPHYSICS
    • G03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03FPHOTOMECHANICAL PRODUCTION OF TEXTURED OR PATTERNED SURFACES, e.g. FOR PRINTING, FOR PROCESSING OF SEMICONDUCTOR DEVICES; MATERIALS THEREFOR; ORIGINALS THEREFOR; APPARATUS SPECIALLY ADAPTED THEREFOR
    • G03F7/00Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printing surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
    • G03F7/20Exposure; Apparatus therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/18Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment

Definitions

  • the present invention relates generally to implantable medical devices and more particularly to controlling surface properties of implantable biocompatible materials suitable for fabrication of implantable medical devices.
  • Implantable medical devices are fabricated of materials that are sub-optimal in terms of the biological response they elicit in vivo.
  • Many conventional materials used to fabricate implantable devices such as titanium, polytetrafluoroethylene, silicone, carbon fiber and polyester, are used because of their strength and physiologically inert characteristics.
  • tissue integration onto these materials is typically slow and inadequate.
  • Certain materials, such as silicone and polyester elicit a significant inflammatory, foreign body response that drives fibrous encapsulation of the synthetic material. The fibrous encapsulation may have significant adverse effects on the implant.
  • conventional biomaterials have proved inadequate in eliciting a sufficient healing response necessary for complete device integration into the body. For example, in devices that contact blood, such as stents and vascular grafts, attempts to modify such devices to promote endothelial cell adhesion may have a concomitant effect of making the devices more thrombogenic.
  • an implantable biocompatible material includes one or more vacuum deposited layers of biocompatible materials deposited upon a biocompatible base material. At least a top most vacuum deposited layer includes a homogeneous molecular pattern of distribution along the surface thereof and comprises a patterned array of geometric physiologically functional features.
  • an implantable biocompatible material in another embodiment, includes a plurality of layers of biocompatible materials formed upon one another into a self-supporting multilayer structure.
  • the plurality of layers includes a vacuum deposited surface layer having a homogeneous molecular pattern of distribution along the surface thereof and comprises a patterned array of geometric physiologically functional features.
  • a method for making an implantable biocompatible material includes the steps of providing an implantable biocompatible material having at least one surface intended to contact tissue of body fluids in vivo and providing a mask having a defined pattern of openings corresponding in size and spacing to a predetermined distribution of binding domains to be imparted to the at least one surface.
  • the method further includes the steps of treating the at least one surface of the biocompatible material through the mask by at least one of three techniques.
  • the first technique includes vacuum depositing a layer of material onto the at least one surface, wherein the vacuum deposited layer is different from the at least one surface immediately therebeneath in a material property selected from the group of material properties consisting of: grain size, grain phase, grain material composition, surface topography, and transition temperature, and removing the mask to yield a plurality of binding domains defined on the at least one surface of the implantable, biocompatible material.
  • the second technique includes vacuum depositing a layer of sacrificial material onto the at least one surface, removing the mask from the at least one surface, vacuum depositing a second layer of material onto the at least one surface, wherein the second vacuum deposited layer is different from the at least one surface immediately therebeneath in a material property selected from the group of material properties consisting of: grain size, grain phase, grain material composition, surface topography, and transition temperature, and removing the sacrificial material to yield a plurality of binding domains defined on the at least one surface of the implantable, biocompatible material.
  • the third technique includes photo irradiating the at least one surface to photochemically alter the at least one surface, and removing the mask to yield a plurality of binding domains defined on the at least one surface of the implantable, biocompatible material.
  • FIG. 1 is a perspective view of one embodiment including evenly distributed elevated geometric physiologically functional features on the surface of an implantable material.
  • FIG. 2 is cross-sectional view of FIG. 1 along line 2 - 2.
  • FIG. 3 is a perspective view of one embodiment including evenly distributed chemically defined geometric physiologically functional features on the surface of an implantable material.
  • FIG. 4 is a cross-sectional view of FIG. 3 along line 4 - 4.
  • FIG. 5 is a photomicrograph showing one embodiment including geometric physiologically functional features as carbon coated silicon.
  • FIGS. 6A-6C are photomicrographs showing cellular migration on the surface with no 5 inventive geometric physiologically functional features versus on the surface with inventive geometric physiologically functional features.
  • FIG. 7 is a photomicrograph showing the stained focal adhesion points close to the geometric physiologically functional features.
  • FIGS. 8A-8B are photomicrographs showing the formation of multiple focal adhesion 0 points of a migrating cell and its attachment to the inventive geometric physiologically functional features.
  • FIGS. 9A-9D are cross-sectional diagrammatic views of one embodiment, the combination of a-d representing the steps to make an inventive implantable material with elevated geometric physiologically functional features.
  • FIGS. 10A-10D are cross-sectional diagrammatic views of one embodiment, the combination of a-d representing the steps to make an inventive implantable material with chemically defined geometric physiologically functional features.
  • FIG. HA illustrates a cross-sectional view of layers of vacuum deposited material
  • FIG. 11B illustrates a cross-sectional view of a mask disposed over a surface of the layers of vacuum ,0 deposited material of FIG. 11 A
  • FIG. 11C illustrates a plan view of the mask of FIG. 11B
  • FIG. HA illustrates a cross-sectional view of layers of vacuum deposited material
  • FIG. 11B illustrates a cross-sectional view of a mask disposed over a surface of the layers of vacuum ,0 deposited material of FIG. 11 A
  • FIG. 11C illustrates a plan view of the mask of FIG. 11B
  • FIG. 11D illustrates a cross-sectional view of material deposited into a space defined by holes of the mask of FIG. 11B; and FIG. HE illustrates a cross-sectional view of geometric physiologically functional features patterned across the surface of FIG. 11B.
  • FIG. 12A illustrates a cross-sectional view of vacuum deposition of a layer of material :5 onto a surface of layers of vacuum deposited material and into a space defined by a sacrificial layer of material previously deposited onto the surface; and FIGS. 12B-12D illustrate a cross- sectional view of recessed geometric physiologically functional features.
  • FIG. 13A illustrates a cross-sectional view of layers of vacuum deposited material deposited over a bulk material; and FIG. 13B illustrates recesses machined to various depths 0 through a surface of the layers of material.
  • FIG. 14 is a schematic of plasma surface modification within a plasma reactor.
  • FIG. 15 is a schematic of the reaction mechanisms of plasma surface modifications.
  • FIG. 16 is a graph of the mean electrostatic force measurements comparing 5 different metal surfaces; measurements were performed using a 5 nm silicon nitride tip in the presence of a 0.01 M. NaCl medium at pH 7.4; force measurement values for each metal represent the mean of data from five different samples on which 5 sites were analyzed using 10 measurements at each site; and mean values were compared using Student's unpaired t-analysis.
  • FIG. 17 is a graph of the correlation of mean electrostatic measurements on the different metal surfaces presented in FIG. 16 with the polar component of total metal surface energy; and total surface energy was calculated by the harmonic method from surface contact angle measurements using water, formamide and xylene as the test liquids.
  • the capacity for complete endothelialization of conventional implantable materials may be enhanced by imparting a pattern of chemically and/or physiochemically active geometric physiologically functional features onto a blood contacting surface of the implantable material.
  • inventive implantable devices may be fabricated of polymers, pre-existing conventional wrought metallic materials, such as stainless steel or nitinol hypotubes, or may be fabricated by thin film vacuum deposition techniques.
  • the inventive implantable devices may be intravascular stent, stent-grafts, grafts, heart valves, venous valves, filters, occlusion devices, catheters, osteal implants, implantable contraceptives, implantable antitumor pellets or rods, shunts and patches, or other implantable medical devices having any construction or made of any material as will be hereinafter described.
  • a medical device is an instrument, apparatus, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body and which does not achieve any of it's primary intended purposes through chemical action within or on the body.
  • intravascular stents are also believed to be applicable to the manufacturing of any type of intravascular medical device, stent-grafts, grafts, heart valves, venous valves, filters, occlusion devices, catheters, osteal implants, implantable contraceptives, implantable antitumor pellets or rods, shunts and patches, pacemakers, medical wires or medical tubes for any type of medical device, or other implantable medical devices, as will also be hereinafter described.
  • a pacemaker or artificial pacemaker, so as not to be confused with the heart's natural pacemaker
  • the electrodes may be covered by tubing or other material that includes a surface that may require endothelialization
  • inventive implantable metal devices may be fabricated of polymers, pre-existing conventional wrought metallic materials, such as stainless steel or nitinol hypotubes, or may be fabricated by thin film vacuum deposition techniques. In accordance with one embodiment, it is preferable to fabricate the inventive implantable materials and resulting devices by vacuum
  • Vacuum deposition permits greater control over many material characteristics and properties of the resulting material and formed device. For example, vacuum deposition permits control over grain size, grain phase, grain material composition, bulk material composition, surface topography, mechanical
  • vacuum deposition processes will permit creation of devices with greater material purity without the introduction of large quantities of contaminants that adversely affect the material and, therefore, the mechanical and/or biological properties of the implanted device. Vacuum deposition techniques also lend themselves to fabrication of more complex devices than those
  • :5 materials in contact with blood flow are preferably controlled by using vacuum deposited materials.
  • the deposited material includes compound species that are formed due to the reaction of the solid source and the gas source, such as in the case of chemical vapor deposition. In most cases, the deposited material is then either partially or completely removed from the substrate, to
  • a first advantage of vacuum deposition processing is that vacuum deposition of the metallic and/or pseudometallic films permits tight process control and films may be deposited that have a regular, homogeneous atomic and molecular pattern of distribution along their fluid- contacting surfaces. This avoids the marked variations in surface composition, creating
  • EC migration is supported by a homogeneous distribution of binding domains that serve as natural or implanted cell attachment sites in order to promote unimpeded migration and attachment.
  • the inventive grafts may be comprised of a layer of biocompatible material or of a plurality of layers of biocompatible materials formed upon one another into a self-supporting multilayer structure because multilayer structures increase the mechanical strength of sheet materials, or to provide special qualities by including layers that have special properties such as superelasticity, shape memory, radio-opacity, corrosion resistance etc.
  • Vacuum deposition :5 technologies may deposit layered materials and thus films possessing exceptional qualities may be produced.
  • Layered materials such as superstructures or multilayers, are commonly deposited to take advantage of some chemical, electronic, or optical property of the material as a coating; a common example is an antireflective coating on an optical lens.
  • Multilayers are also used in the field of thin film fabrication to increase the mechanical properties of the thin film, specifically 0 hardness and toughness.
  • Conventional wrought metal fabrication techniques may entail smelting, hot working, cold working, heat treatment, high temperature annealing, precipitation annealing, grinding, ablation, wet etching, dry etching, cutting and welding. All of these processing steps have disadvantages including contamination, material property
  • the embodiments disclosed herein takes advantage of the discovered relationship 5 between chemically or physiochemically-active geometric physiologically functional features defined and distributed on a blood contact surface and enhanced endothelial cell binding, proliferation and migration over the blood contact surface of the implantable material.
  • the embodiments disclosed herein involve focal adhesion point formation during cellular movement and the anchorage dependence, that spreading cells proliferate faster than non-spreading cells. :0
  • the geometric physiologically functional features disclosed herein may be formed on, in, or through one or more layers of vacuum deposited biocompatible material.
  • the one or more layers of vacuum deposited biocompatible material are deposited on a layer of bulk material.
  • a plurality of layers of vacuum deposited biocompatible material is deposited on one another to form a self-supporting multilayer
  • the geometric physiologically functional features may have a non-zero thickness corresponding to a thickness of one or more layers of the vacuum deposited material.
  • the geometric physiologically functional features may have a zero thickness or a thickness greater than one or more layers of the vacuum deposited material.
  • Geometric physiologically functional features having thicknesses greater than 3 ⁇ and up to about 20 ⁇ may also be employed in the embodiments disclosed herein, it being understood that as the thickness of the geometric physiologically functional feature increases there is a decreasing chemical and/or electrochemical interaction between the geometric physiologically 0 functional feature and the endothelial cells and an increasing physical interaction (topographic guidance effect).
  • UV irradiation may be employed to oxidize titanium or titanium-alloy surfaces, photochemical alteration of the surface titanium oxides alter the hydrophobicity of the exposed titanium oxides and act as affinity binding and migration sites for endothelial cell
  • the thickness of the photochemically altered regions of titanium oxide are, for all practical purposes, 0 ⁇ .
  • the term "geometric physiologically functional features" is intended to include both physical members and photochemically-altered regions having thicknesses having thicknesses down to 0 ⁇ .
  • FIG. 1 a portion of an implantable material 10 showing the surface material 12 with described elevated geometric physiologically functional features 14 is illustrated.
  • the geometric physiologically functional features are elevated from the surface of the implantable material to a height ranging from about 1 nm to about 20 ⁇ .
  • the height of the geometric physiologically functional feature 14 ranges from about 1 nm to about 3 ⁇ .
  • geometric physiologically functional features can be either circular, square, rectangle, triangle, parallel lines, straight or curvilinear lines or any combination thereof.
  • Each of the geometric physiologically functional features is preferably from about 1 nm to about 75 ⁇ , and preferably from about lnm to 50 ⁇ in feature width 16, or feature diameter if the geometric physiologically functional feature is circular.
  • FIG. 2 is a cross-sectional view along line 2-2 in FIG. 1.
  • One of the elevated geometric physiologically functional features 14 is shown on the surface 12 of the implantable material.
  • a layer of a titanium or titanium-alloy material 20 is heating to oxidize and form titanium dioxide on the surface of the material 20.
  • the layer of titanium or titanium-alloy material 20 is deposited over one or more layers of vacuum deposited material in a self-supporting multilayer structure.
  • the layer of titanium or titanium-alloy material 20 is deposited over a bulk material that may have one or more layers of vacuum deposited material deposited thereon.
  • the geometric physiologically functional features 24 are formed by exposing the layer of material 20 to UV through a pattern mask. UV irradiation alters the titanium oxides in the areas of geometric physiologically functional features 24, thereby chemically altering the geometric physiologically functional features 24 relative to the surrounding the surrounding surface area 22 of material layer of material 20.
  • the shape of geometric physiologically functional features can be circular, square, rectangle, triangle, parallel lines, intersecting lines or any combination.
  • Each of the geometric physiologically functional features is from about 1 nanometer to about 75 ⁇ , and preferably from about 1 nanometer to about 50 ⁇ in feature width 16, or feature diameter if the geometric physiologically functional feature is circular.
  • the gap distance 28 between each component of the geometric physiologically functional features may be less than, about equal to or greater than the feature width 26.
  • FIG. 4 is a cross-sectional view of FIG. 3 along line 4-4.
  • the described geometric physiologically functional features 24 are indicated by the dotted lines, which indicate that the geometric physiologically functional features 24 are at the same level of the surrounding surface 22.
  • FIG. 5 shows geometric physiologically functional features that are evenly distributed across the at least one surface of the implantable material that contacts body fluid, preferably blood.
  • the geometric physiologically functional features are elevated from the rest of the surface to a height ranging from about 1 nanometer to about 20 micrometers.
  • the height of the geometric physiologically functional feature ranges from about 1 nanometer to about 3 micrometers.
  • the shape of the geometric physiologically functional features is not confined within the shape that is shown.
  • the shape of the chemically defined domain can also be any of circle, square, rectangle, and triangle, parallel lines, intersecting lines or any combination of the above.
  • FIG. 6A shows the cell 32 spreading on the surface of hydrophilic treated Si.
  • FIG. 6B shows the cell 32 spreading on the surface of hydrophilic treated Si with circular dots that are 15
  • each of these affinity domains determines the availability of affinity domains to the subsequent round of cell movement. According to one embodiment, the preferred size of each of the individual
  • 0 component of the geometric physiologically functional features is about 1 nm to about 75 ⁇ , and preferably from about 1 nm to 50 ⁇ in feature width, or diameter if the geometric physiologically functional feature is circular.
  • Focal adhesion point formation is the critical step in cell movement and cell proliferation; therefore, geometric physiologically functional features such as carbon dots on the hydrophilic Si surface promote cell movement.
  • FIG. 6C is a magnification of a portion of the image of FIG. 6B. Multiple focal adhesion points 36 are again shown. Wide spreading of the cell is primarily due to the formation of multiple focal adhesion points on the circular geometric physiologically functional features. Extensive spreading of the cells is beneficial towards endothelialization because it promotes cell
  • FIG. 7 shows the stained focal adhesion points 36 of human aotic endothelial cells (HAEC) on the surface of an implantable material with geometric physiologically functional features 14 that are in the form of carbon dots.
  • the focal adhesion points are located at or very close to the geometric physiologically functional features 14.
  • FIG. 8A shows the wide spreading of cells 32 and focal multiple focal adhesion points 36 on the surface of an implantable material with geometric physiologically functional features that are in the form of NiTi dots of 25 micrometers in diameter. The NiTi dots are invisible due to the weak contrast between the NiTi dots and surrounding Si surface.
  • FIG. 8B shows a magnified slide of a human aortic epithelial cell 32, as shown in FIG. 8 A. Multiple focal adhesion points 36 are shown to encapsulate the NiTi dots patterned on the hydrophilic Si surface.
  • FIG. 9A a portion of an implantable material 46 with surface 42 and 44 is shown.
  • a machined mask 48 having laser-cut holes 40 of defined size ranging from about 1 nm to about 75 ⁇ , and preferably from about 1 nm to 50 ⁇ , patterned throughout coats at least one surface 42 of the implantable material 46 and is tightly adhered to the covered surface 42.
  • a thin film of material 14 was deposited into the space as defined by the holes 40, as seen in FIG. 9B, in the mask 48 by thin film deposition procedures.
  • the mask is removed to reveal the geometric physiologically functional features 49 patterned across the at least one surface 42 of the implantable material 46.
  • the shape of the holes in the mask could be in any of the shapes described for the geometric physiologically functional features including: circle, square, rectangle, triangle, parallel lines and intersecting lines, or any combination thereof.
  • the geometric physiologically functional features are elevated from the surface of the implantable material.
  • the thickness of the geometric physiologically functional features is based upon the thickness of the holes in the mask, the thickness ranging from about 1 nm to about 20 micrometers. Preferably, the thickness of the holes in the mask range from about 1 nm to about 3 micrometers.
  • the variations of geometric physiologically functional features may be added to a surface of an implantable biocompatible material by vacuum depositing a layer or layers of biocompatible material on the surface.
  • the geometry of the layer or layers of deposited material defines the geometric physiologically functional features.
  • an implantable material 100 has a surface 104, as illustrated in FIG. 11 A.
  • the implantable biocompatible material may comprise one or more layers 102 of vacuum deposited material formed into a self-supporting structure, as illustrated by FIG. 11A showing a first layer 102a, a second layer 102b, a third layer 102c, a fourth layer 102d, and a fifth layer 102e.
  • the implantable biocompatible material includes a bulk material, either a bulk material alone or a bulk material covered by the one or more layers 102a-102e of vacuum deposited biocompatible material. Five layers 102a-102e of vacuum deposited material are
  • the one or more layers 102 may have thicknesses that are the same or different as desired or appropriate. Each layer may have a thickness in a range from about 1 nanometer to about 20 micrometers, from about 1 nanometer to about 10 micrometers, from about 1 nanometer to about 5 micrometers, or from about 1 nanometer to about 3 micrometers. Alternating layers
  • 0 102 of varying thicknesses may be applied as to accommodate the geometric physiologically functional features.
  • the geometric physiologically functional features may be added to the surface 104 by adding one or more layers 102 of vacuum deposited material.
  • a mask 106 having holes 108 of defined size may be added to the surface 104 by adding one or more layers 102 of vacuum deposited material.
  • the holes 108 may be cut through the mask 106, for example, by using a laser, wet or dry chemical etching, or other like methods for forming holes through a material, or the mask 106 may be fabricated including the holes 108.
  • the thickness of the holes 108 may range about 1 nanometer to about 20 micrometers, from about 1 nanometer to about 10
  • micrometers from about 1 nanometer to about 5 micrometers, or from about 1 nanometer to about 3 micrometers.
  • the shape of the holes 108 as seen in FIG. 11C or as looking in the direction of arrow 110 may be any of the shapes described for the geometric physiologically functional features including: circle, square, rectangle, triangle, polygonal, hexagonal, octagonal, elliptical, parallel
  • the holes 108 may have a width 112, or diameter 112 if the holes are circular, in a range between about 1 nanometer and about 75 micrometers, between about 1 nanometer and about 50 micrometers, between about 1 nanometer and about 2000 nanometers, or between about 1 nanometer and about 200 nanometers. Adjacent holes 108 may be spaced apart by a distance D in a range from about 1 nanometer to about 20
  • the distance D may be less than, about equal to or greater than the width 112.
  • the width 112 of each of the holes 108 and/or the distance D between adjacent holes 108 may vary in size to form a patterned array of the holes 108.
  • a layer 114 of material was deposited into a space as defined by 5 the holes 108 in the mask 106 by vacuum deposition.
  • the layer 114 has a thickness essentially the same as that of the mask 106. In some embodiments, the thickness of the mask may be variable across the mask 106.
  • geometric physiologically functional features 116 are revealed patterned across the surface 104 of the implantable material 100. Each of the geometric physiologically functional features 116 includes a top surface 118. 0 Each of the geometric physiologically functional features 116 has dimensions as described hereinabove for the holes 108 in the mask 106.
  • a patterned array of recesses may be formed each having a hydrophobic, hydrophilic or surface energy difference relative to the
  • hydrophobic, hydrophilic or surface energy differences relative to the surface may be formed, by way of example, any of the methods disclosed in commonly assigned U.S. Patent Application No. 12/428,981, filed April,
  • the recesses may be formed by a relative lack of deposition of a layer or layers onto a surface, or by machining recesses through a layer or layers of material vacuum deposited on a surface.
  • a pattern of recesses similar to the pattern of geometric physiologically functional features 116 illustrated in FIG. HE in one example, a
  • the layer 114 of material is a sacrificial layer of material that is removed in a subsequent step.
  • a layer 120 of material is deposited into spaces 0 between the geometric physiologically functional features 116 by vacuum deposition.
  • the layer 120 has a thickness essentially the same as that of the geometric physiologically functional features 116.
  • the geometric physiologically functional features 116 of the sacrificial layer 114 are removed, for example, by chemical etching, photo etching, laser ablation, or other method reveal geometric physiologically functional features 122 patterned across the surface 104 of the implantable material 100.
  • Each of the geometric physiologically functional features 122 is a recess that has a thickness or depth between a surface 124 of the layer 120 and the surface 104.
  • the shape of the recesses 122 as seen looking in the direction of arrow 126 in FIG. 12B may be any of the shapes described for the geometric physiologically functional features including: circle, square, rectangle, triangle, polygonal, hexagonal, octagonal, elliptical, parallel lines and intersecting lines, or any combination thereof.
  • the recesses 122 may have the width 112, or diameter if the recesses 122 are circular, in a range between about 1 nanometer and about 75 micrometers, alternatively between about 1 nanometer and about 50 micrometers, alternatively between about 1 nanometer and about 2000 nanometers, or alternatively between about 1 nanometer and about 200 nanometers.
  • Adjacent recesses 122 may be spaced apart by the distance D in a range from about 1 nanometer to about 20 micrometers, from about 1 nanometer to about 10 micrometers, from about 1 nanometer to about 5 micrometers, or from about 1 nanometer to about 3 micrometers.
  • the distance D may be less than, about equal to or greater than the width 112.
  • the width 112 of each of the recesses 122 and/or the distance D between adjacent recesses 122 may vary in size to form a patterned array of the recesses 122.
  • the recesses 122 having width and spacing as described hereinabove with regard to FIGS. 12A and 12B may be formed by machining the recesses 122 through a layer or layers 128 of vacuum deposited material.
  • an implantable material 130 having a surface 132 may comprise a bulk material 134, the one or more layers 128 of vacuum deposited material, or the bulk material 134 and the one or more layers 128 of vacuum deposited material, as illustrated in FIG. 13A.
  • the geometric physiologically functional features 116 themselves include a plurality of deposited layers, wherein the geometric physiologically functional features 116 include the first layer 102a, the second layer 102b, and the third layer 102c.
  • the geometric physiologically functional features 116 are deposited through a mask as previously indicated, on top of structural material of the stent or other medical device include deposited layer 102d and 102e.
  • the geometric physiologically functional features 116 include the first layer 102a and the second layer 102b, deposited through the mask whereby the structural material of the stent or other medical device includes the layers 102c-102d.
  • the geometric physiologically functional features 116 include the first layer 102a,
  • the thickness of the layers as deposited can be modified to be a narrower or decreased thickness as to allow for the geometric physiologically functional feature 116 to be adjusted to a particular thickness.
  • layers of different vacuum deposited materials can be deposited to create the elevated surfaces having inherently different material properties.
  • layers of the same vacuum deposited material can be deposited having differences in grain size, grain phase, and/or surface topography or variations of hydrophobic, hydrophilic or surface energy difference relative to the surface of the stent or structural material.
  • the recesses 122 may include a plurality of layers ,0 102 to provide for differences in grain size, grain phase, and/or surface topography or variations of hydrophobic, hydrophilic or surface energy difference relative to the surface of the stent or structural material.
  • the recesses 122 may be formed by the surface 124 being deposited through a mask as to form the layer 120 that gives rise to the plurality of recesses 122 with a wall 123.
  • the recesses 122 include an inner wall 123 including the first layer 102a, the second layer :5 102b, and the third layer 102c, whereby the surface 104 is on layer 102d, which is exposed on the bottom of the recess 122 and surface 124 is on top of layer 102a.
  • the recesses 122 may include a wall of the first layer 102a and the second layer 102b, whereby the surfaces 124 are deposited through a mask, and the structural material of the stent or other medical device includes the layers 102d-102e.
  • the recesses 122 include a wall of the first layer 0 102a, the second layer 102b, the third layer 102c, and the fourth layer 102d, and surfaces 124 are deposited through a mask whereby surface 102e that acts as the surface 104 of the structural material of the medical device.
  • additional layers 102a-102d are included as the wall in the geometric physiologically functional feature 116, the thickness of the layers as deposited can be modified to be a narrower or decreased thickness as to allow for the geometric physiologically functional feature 116 to be adjusted to a particular thickness.
  • deposited materials can be deposited to create recesses having inherently different material properties.
  • layers of the same vacuum deposited material can be deposited having differences in grain size, grain phase, and/or surface topography or variations of hydrophobic, hydrophilic or surface energy difference relative to the surface of the stent or structural material.
  • recesses 136 may be machined into the surface 132 of the
  • each of the recesses 138 may be machined into the surface 132 of the implantable material 130 to have a depth greater than a thickness of the first and second layers 128a, 128b of material.
  • Two layers are illustrated for convenience of explanation and illustration; however, any number of layers 128 of material may be used as desired or appropriate.
  • each of the recesses may be machined into the surface 132 of the implantable material 130 to have a depth greater than a thickness of the first and second layers 128a, 128b of material.
  • each of the recesses 138 has a thickness or depth between the surface 132 of the layer 128a and a surface 142 that is within the bulk material 134.
  • An implantable material including geometric physiologically functional features comprising a layer or layers of vacuum deposited material, as illustrated by the geometric
  • layers of different vacuum deposited materials can be deposited to create recessed and/or elevated surfaces having inherently different material properties.
  • layers 0 of the same vacuum deposited material can be deposited having differences in grain size, grain phase, and/or surface topography.
  • the alternative grain size, grain phase, and/or surface topography may be included or formed, by way of example, any of the methods disclosed in commonly assigned U.S. Patent Application No. 12/428,981 , filed April, 23, 2009, incorporated by reference herein.
  • surfaces of the recesses 122, 136 can be deposited to have a roughened surface topography and a large grain size and surfaces of the material deposited defining the recesses 122, 136, for example the layer 120 illustrated in FIG.
  • a factor in increasing endothelialization of a surface of an implanted medical device may be the cleanliness of the surface.
  • cleanliness refers to the presence or lack of contaminant molecules bonding to otherwise unsaturated chemical bonds at the surface.
  • a perfectly clean surface for example as may exist in a vacuum, comprises unsaturated bonds at the surface that have not bound to any contaminant molecules. The unsaturated bonds provide the surface with a higher surface energy as compared to a contaminated surface having fewer unsaturated bonds, which have a lower surface energy. Measurements of surface energy may be accomplished by contact angle measurements, as disclosed in U.S. Patent Application Serial No. 12/428,981 , which was filed April, 23, 2009.
  • the air atmosphere around the surface include normally occurring impurities which will be attracted to the unsaturated chemical bonds at levels in the air around 1x109 to 1x106 so it will take a few seconds before the surface is contaminated by their Brownian motion, after 1 min, most of the unsaturated bond are saturated with contaminants.
  • One molecular monolayer i.e. a single layer of molecules
  • additional molecules may bond to the surface and build multi-layers of contaminant molecules.
  • the surface of a few molecular monolayers of contaminants may have thickness of about 0.1- 2nm, which may be detected by sensitive surface analysis as indicated above.
  • a cleaner surface having more unsaturated bonds provides increased potential for interaction with blood proteins. It is contemplated that a
  • contaminated surface of a vacuum deposited or bulk material can be activated, or made more likely to interact with blood proteins, by removing the contaminant molecules that occupy the otherwise unsaturated bonds at the surface.
  • activation There may be several techniques for accomplishing such activation, including by way of example and not limitation, chemical etching, wet chemical etching, oxidation, electrochemical treatment, thermal treatment, UV-ozone cleaning, coating by
  • a vacuum deposited surface may be by using plasma electron bombardment under vacuum, a technique also known as plasma etching.
  • the contaminant layer may be detected by surface-sensitive spectrosscopies, such as Auger electron spectroscopy (AES), x-ray photoemission spectroscopy (XPS or ESC), infrared reflection absorption spectroscopy (IRAS, FT-IR, etc.) secondary ion mass spectroscopy
  • AES Auger electron spectroscopy
  • XPS x-ray photoemission spectroscopy
  • IRAS infrared reflection absorption spectroscopy
  • FT-IR FT-IR
  • Plasma etching the sample to be treated is positioned within a controlled electrical gas discharge (a plasma), as schematically shown in FIG. 14.
  • the plasma may be formed by applying a high voltage (AC or DC) over a gas under considerably lower pressure than one atmosphere (typically 0.1-lmm Hg, or a vacuum). Because of the low pressure and because gas
  • the discharge and the sample must be housed in a hermetically closed system that can be evacuated by vacuum pumps, and whose gas composition can be controlled.
  • the plasma also has sufficient energy and momentum to remove atoms and molecules that are adsorbed on unsaturated bonds, or are constituents of the native surface. As such, the contamination layer bond to unsaturated bonds may be removed, to recreate the
  • the surface treatment can be mild (mainly removal of the contamination layer) or more aggressive.
  • the complete surface oxide layer on a metal may be removed so that the bare metal is exposed. The latter occurs only provided that no oxidizing or
  • the used gas must be a noble gas such as Ar, Kr, or Xe.
  • the composition of the newly formed surface is controlled; if oxygen is added, oxide will be formed; if nitrogen or hydrocarbons are added, surface nitride or surface carbide, respectively, will form, etc.
  • the gas purity must be high, as impurities within the gas will react to the high energy cleaned surfaces.
  • the activated surface may be preserved by introducing a contaminant gas or liquid into the plasma etching process in a controlled manner, which may be easily removed before use of the medical device.
  • the 0 contaminant layer may be a known biodegradable material or may be a contaminant layer or coating of inorganic or organic nature or a mixture of both.
  • the contaminant layer may be layer readily removed by a saline or water solution, which are typically used in flushing procedures or washing procedures.
  • the activated surface may be coated with a protective coating, for example,
  • the biodegradable material may alternatively be dissolved via introduction of an externally delivered fluid solvent during implantation.
  • the protective coating may be a fluid in which the activated device is immersed until implantation. For example, it is contemplated that storing the activated surface in water facilitates preservation of the activation
  • the biodegradable material may be any material, natural or synthetic, that may be broken down by living organisms, including, but not limited to a biodegradable organic substance, biodegradable polymer substances (Poly(lactic acid) PLA, poly(L-lactic acid) (PLLA), poly(lactic-co-glycolic acid) PLGA, poly(glycolicacid) (PGA), Polyethylene glycol, PEG, polytetrafluoroethylene (PTFE), and the like), peptides or
  • the method disclosed herein comprehends the creation of a patterned array of geometric physiologically functional features elevated relative to a surface of an implantable biocompatible material, recessed relative to the surface, or disposed on the surface.
  • the implantable biocompatible material is formed of a bulk
  • the titanium, nickel-titanium alloy or other titanium-rich alloy metal is oxidized to convert surface titanium to titanium dioxide, then covered with a pattern-mask and exposed to high intensity UV irradiation. It is well-known that titanium dioxide (Ti0 2 ) absorbs UV radiation
  • the amphiphilic state of the UV irradiated titanium oxide may be advantageously employed as an alternative to depositing patterned elevated or recessed geometric physiologically functional features onto the implantable biocompatible material.
  • the plurality of openings preferably have a size and special array selected to define affinity binding domains and cellular migration cites for promoting endothelial cell binding and proliferation across the substrate surface.
  • each of the plurality of openings in the pattern mask is preferably in the range of between about lnm to about 75 ⁇ , and with adjacent pairs of openings being in a spaced apart relationship such that a distance of about lnm to about 75 ⁇ exists between the openings, the inter-opening being greater than, about equal to, or less than the size of the opening.
  • an implantable material 56 made of titanium or a titanium-alloy having at least one surface 52 and 54 that is oxidized by heating or an
  • a machined mask 48 that had laser-cut holes 40 of defined size from about 1 nm to about 75 um, from about 1 nm to about 50 ⁇ , from about 1 nm to about 2000 nm, and preferably from about 1 nm to about 200 nm, patterned throughout to coat the at least one surface 52 of the implantable material 56 and is tightly adhered to the covered surface 52.
  • the implantable material 56 covered with the mask 48 is then illuminated by the ultraviolet rays. Because Ti0 2 is sensitive to ultraviolet, the chemical composition in holes 58 is different from the area that is covered by the mask. In contrast to the geometric physiologically functional features illustrated in FIGS. 9C, HE, 12B, and 13B, the geometric physiologically functional features 59 in FIG. IOC are not elevated and therefore have
  • the mask is removed to reveal the surface 52 that surrounds the geometric physiologically functional features 59 formed by ultraviolet irradiation.
  • the shape of the holes 58 in the mask 48 could be in any of the shapes described for the geometric physiologically functional features
  • Nickel-titanium sheets were heated to oxidize titanium present at the surface of the sheet.
  • 0 Pattern masks fabricated from machined metal were laser drilled a pattern of holes having diameters ranging from 15 ⁇ to 50 ⁇ , with a single diameter of holes on each pattern mask.
  • a single pattern mask was placed over a single nickel-titanium sheet and the assembly was exposed to high intensity ultra-violet irradiation. After UV irradiation, the irradiated nickel-titanium sheet was placed on a fully endothelialized test surface and maintained at 37° C. under simulated in vivo flow conditions and under static flow conditions.
  • Glow discharge plasma treatment is a method of cleaning and removing surface contaminants from metallic as well as other surfaces, schematically shown in FIG. 15.
  • Glow 0 discharge treatment of many metallic surfaces causes their surfaces to change from very hydrophobic surfaces on which water beads to a hydrophilic surface on which water rapidly spreads. This can be quantitatively measured using contact angle measurement techniques, described above.
  • contact angle measurement techniques described above.
  • a change in water contact angle was measured from 98° prior to treatment to 7° after glow discharge.
  • Gold, stainless steel and electropolished Nitinol all exhibit net attractive forces subsequent to glow discharge treatment, as shown in FIG. 16. Nitinol and gold now exhibit highly attractive forces that are significantly higher (p ⁇ .001) than that observed on stainless steel.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
PCT/US2012/037776 2011-05-13 2012-05-14 Implantable materials having engineered surfaces and method of making same Ceased WO2012158614A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2012255972A AU2012255972B2 (en) 2011-05-13 2012-05-14 Implantable materials having engineered surfaces and method of making same
CN201280031581.4A CN103619364A (zh) 2011-05-13 2012-05-14 具有工程表面的可植入材料和其制造方法
MX2013013139A MX2013013139A (es) 2011-05-13 2012-05-14 Materiales implantables que tienen superficies manipuladas, y metodos para fabricarlos.
EP12786428.8A EP2707044B1 (en) 2011-05-13 2012-05-14 Implantable materials having engineered surfaces and method of making same
JP2014510536A JP2014514127A (ja) 2011-05-13 2012-05-14 システム表面およびその製造方法を有する移植用材料
CA2835844A CA2835844C (en) 2011-05-13 2012-05-14 Implantable materials having engineered surfaces and method of making same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/107,510 2011-05-13
US13/107,510 US8679517B2 (en) 2002-09-26 2011-05-13 Implantable materials having engineered surfaces made by vacuum deposition and method of making same

Publications (2)

Publication Number Publication Date
WO2012158614A2 true WO2012158614A2 (en) 2012-11-22
WO2012158614A3 WO2012158614A3 (en) 2013-01-10

Family

ID=47177584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/037776 Ceased WO2012158614A2 (en) 2011-05-13 2012-05-14 Implantable materials having engineered surfaces and method of making same

Country Status (8)

Country Link
US (4) US8679517B2 (enExample)
EP (1) EP2707044B1 (enExample)
JP (1) JP2014514127A (enExample)
CN (1) CN103619364A (enExample)
AU (1) AU2012255972B2 (enExample)
CA (1) CA2835844C (enExample)
MX (1) MX2013013139A (enExample)
WO (1) WO2012158614A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8458879B2 (en) * 2001-07-03 2013-06-11 Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. Method of fabricating an implantable medical device
US8679517B2 (en) * 2002-09-26 2014-03-25 Palmaz Scientific, Inc. Implantable materials having engineered surfaces made by vacuum deposition and method of making same
GB0724736D0 (en) 2007-12-19 2008-01-30 Oxford Nanolabs Ltd Formation of layers of amphiphilic molecules
EP2422827B1 (en) * 2010-08-27 2019-01-30 Biotronik AG Stent with a surface layer having a topographic modification
CH705978A1 (de) * 2012-01-11 2013-07-15 Qvanteq Ag Verfahren und Vorrichtung zur Bestimmung einer Oberflächencharakteristik an Stents und Stent mit definierter Oberflächencharakteristik.
GB201202519D0 (en) * 2012-02-13 2012-03-28 Oxford Nanopore Tech Ltd Apparatus for supporting an array of layers of amphiphilic molecules and method of forming an array of layers of amphiphilic molecules
GB201313121D0 (en) 2013-07-23 2013-09-04 Oxford Nanopore Tech Ltd Array of volumes of polar medium
CN103861155A (zh) * 2014-03-11 2014-06-18 郑欣 一种具有诱导细胞增殖分化能力的纳米形貌芯片
US10687956B2 (en) 2014-06-17 2020-06-23 Titan Spine, Inc. Corpectomy implants with roughened bioactive lateral surfaces
TWI726940B (zh) 2015-11-20 2021-05-11 美商泰坦脊柱股份有限公司 積層製造整形外科植入物之方法
GB201611770D0 (en) 2016-07-06 2016-08-17 Oxford Nanopore Tech Microfluidic device
EP3493768A1 (en) 2016-08-03 2019-06-12 Titan Spine, Inc. Implant surfaces that enhance osteoinduction
CN107789666A (zh) * 2016-08-30 2018-03-13 北京航空航天大学 一种内壁微图案化小口径人造血管
CN110366435A (zh) * 2017-02-24 2019-10-22 扩凡科技有限公司 用于植入物的表面密封物
US10373767B2 (en) 2017-11-21 2019-08-06 Vactronix Scientific, Llc Structural supercapacitor composite and method of making same
GB2568895B (en) 2017-11-29 2021-10-27 Oxford Nanopore Tech Ltd Microfluidic device
US11457932B2 (en) 2018-03-15 2022-10-04 Mako Surgical Corp. Robotically controlled water jet cutting
KR20210138594A (ko) 2019-03-12 2021-11-19 옥스포드 나노포어 테크놀로지즈 피엘씨 나노포어 감지 디바이스 및 이를 작동하는 방법 및 형성하는 방법
CN111973814B (zh) * 2019-05-21 2024-04-19 中国人民解放军军事科学院军事医学研究院 一种具有复合仿生界面的血管支架及其制备方法
WO2022013551A1 (en) 2020-07-17 2022-01-20 Oxford Nanopore Technologies Limited Nanopore sensing device

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387247A (en) 1983-10-25 1995-02-07 Sorin Biomedia S.P.A. Prosthetic device having a biocompatible carbon film thereon and a method of and apparatus for forming such device
US4657544A (en) 1984-04-18 1987-04-14 Cordis Corporation Cardiovascular graft and method of forming same
WO1987005038A1 (en) 1986-02-17 1987-08-27 Commonwealth Scientific And Industrial Research Or Implantable materials
IT1196836B (it) 1986-12-12 1988-11-25 Sorin Biomedica Spa Protesi in materiale polimerico con rivestimento di carbonio biocompatibile
US5133845A (en) 1986-12-12 1992-07-28 Sorin Biomedica, S.P.A. Method for making prosthesis of polymeric material coated with biocompatible carbon
US5079600A (en) 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
US5588443A (en) 1989-07-25 1996-12-31 Smith & Nephew Richards, Inc. Zirconium oxide and zirconium nitride coated guide wires
US5278063A (en) 1989-09-28 1994-01-11 Board Of Regents The University Of Texas System Chemical modification of promote animal cell adhesion on surfaces
US5477864A (en) 1989-12-21 1995-12-26 Smith & Nephew Richards, Inc. Cardiovascular guidewire of enhanced biocompatibility
US5207709A (en) 1991-11-13 1993-05-04 Picha George J Implant with textured surface
CA2087132A1 (en) 1992-01-31 1993-08-01 Michael S. Williams Stent capable of attachment within a body lumen
SE500657C2 (sv) * 1992-12-07 1994-08-01 Nobelpharma Ab Metod och anordning för preparering av implantatytor med användning av gasurladdningsplasma
BE1006440A3 (fr) 1992-12-21 1994-08-30 Dereume Jean Pierre Georges Em Endoprothese luminale et son procede de preparation.
US5607463A (en) 1993-03-30 1997-03-04 Medtronic, Inc. Intravascular medical device
US5658443A (en) 1993-07-23 1997-08-19 Matsushita Electric Industrial Co., Ltd. Biosensor and method for producing the same
US5645740A (en) 1993-11-01 1997-07-08 Naiman; Charles S. System and assemblage for producing microtexturized substrates and implants
US20010039454A1 (en) 1993-11-02 2001-11-08 John Ricci Orthopedic implants having ordered microgeometric surface patterns
EP0701803B1 (en) 1994-02-03 1999-10-06 SYNTHES AG Chur Medical device for implantation into living bodies
US5733303A (en) 1994-03-17 1998-03-31 Medinol Ltd. Flexible expandable stent
US5725573A (en) 1994-03-29 1998-03-10 Southwest Research Institute Medical implants made of metal alloys bearing cohesive diamond like carbon coatings
JPH07284527A (ja) 1994-04-18 1995-10-31 Ishikawajima Harima Heavy Ind Co Ltd 生体用金属およびその使用法
DE4429380C1 (de) * 1994-08-15 1996-04-25 Biotronik Mess & Therapieg Verfahren zur Herstellung einer nichtkollabierenden intravasalen Gefäßprothese (Stent)
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5607475A (en) 1995-08-22 1997-03-04 Medtronic, Inc. Biocompatible medical article and method
US6001622A (en) 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
JPH09225021A (ja) 1995-12-22 1997-09-02 Toto Ltd 医用材料
US5843289A (en) 1996-01-22 1998-12-01 Etex Corporation Surface modification of medical implants
NZ331269A (en) 1996-04-10 2000-01-28 Advanced Cardiovascular System Expandable stent, its structural strength varying along its length
US5932299A (en) 1996-04-23 1999-08-03 Katoot; Mohammad W. Method for modifying the surface of an object
US5769884A (en) 1996-06-27 1998-06-23 Cordis Corporation Controlled porosity endovascular implant
US6007573A (en) 1996-09-18 1999-12-28 Microtherapeutics, Inc. Intracranial stent and method of use
US5895419A (en) 1996-09-30 1999-04-20 St. Jude Medical, Inc. Coated prosthetic cardiac device
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US5902475A (en) 1997-04-08 1999-05-11 Interventional Technologies, Inc. Method for manufacturing a stent
US6240616B1 (en) 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US5891507A (en) 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US5980564A (en) 1997-08-01 1999-11-09 Schneider (Usa) Inc. Bioabsorbable implantable endoprosthesis with reservoir
US5897911A (en) 1997-08-11 1999-04-27 Advanced Cardiovascular Systems, Inc. Polymer-coated stent structure
US6143370A (en) 1997-08-27 2000-11-07 Northeastern University Process for producing polymer coatings with various porosities and surface areas
WO1999023977A1 (en) 1997-11-07 1999-05-20 Expandable Grafts Partnership Intravascular stent and method for manufacturing an intravascular stent
US5955588A (en) 1997-12-22 1999-09-21 Innerdyne, Inc. Non-thrombogenic coating composition and methods for using same
US6077413A (en) 1998-02-06 2000-06-20 The Cleveland Clinic Foundation Method of making a radioactive stent
US6140127A (en) 1998-02-18 2000-10-31 Cordis Corporation Method of coating an intravascular stent with an endothelial cell adhesive five amino acid peptide
US6280467B1 (en) 1998-02-26 2001-08-28 World Medical Manufacturing Corporation Delivery system for deployment and endovascular assembly of a multi-stage stented graft
US6103320A (en) 1998-03-05 2000-08-15 Shincron Co., Ltd. Method for forming a thin film of a metal compound by vacuum deposition
JP3735461B2 (ja) 1998-03-27 2006-01-18 株式会社シンクロン 複合金属の化合物薄膜形成方法及びその薄膜形成装置
DE19916086B4 (de) 1998-04-11 2004-11-11 Inflow Dynamics Inc. Implantierbare Prothese, insbesondere Gefäßprothese (Stent)
US6261322B1 (en) 1998-05-14 2001-07-17 Hayes Medical, Inc. Implant with composite coating
US6086773A (en) 1998-05-22 2000-07-11 Bmc Industries, Inc. Method and apparatus for etching-manufacture of cylindrical elements
US6387060B1 (en) 1998-06-17 2002-05-14 Advanced Cardiovascular Systems, Inc. Composite radiopaque intracorporeal product
US6096175A (en) 1998-07-17 2000-08-01 Micro Therapeutics, Inc. Thin film stent
US6159239A (en) 1998-08-14 2000-12-12 Prodesco, Inc. Woven stent/graft structure
MXPA01003283A (es) 1998-09-30 2002-07-02 Impra Inc Mecanismo de suministro para un dispositivo de stent implantable.
US6325825B1 (en) 1999-04-08 2001-12-04 Cordis Corporation Stent with variable wall thickness
US6253441B1 (en) 1999-04-16 2001-07-03 General Electric Company Fabrication of articles having a coating deposited through a mask
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6334868B1 (en) 1999-10-08 2002-01-01 Advanced Cardiovascular Systems, Inc. Stent cover
US7300457B2 (en) 1999-11-19 2007-11-27 Advanced Bio Prosthetic Surfaces, Ltd. Self-supporting metallic implantable grafts, compliant implantable medical devices and methods of making same
US6936066B2 (en) 1999-11-19 2005-08-30 Advanced Bio Prosthetic Surfaces, Ltd. Complaint implantable medical devices and methods of making same
US6537310B1 (en) 1999-11-19 2003-03-25 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal implantable devices and method of making same
US6379383B1 (en) 1999-11-19 2002-04-30 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal device exhibiting improved endothelialization and method of manufacture thereof
US6849085B2 (en) 1999-11-19 2005-02-01 Advanced Bio Prosthetic Surfaces, Ltd. Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same
US6533905B2 (en) 2000-01-24 2003-03-18 Tini Alloy Company Method for sputtering tini shape-memory alloys
KR100860860B1 (ko) 2000-03-15 2008-09-29 오르버스네이치 메디칼 인코포레이티드 내피 세포 부착을 촉진하는 코팅
US6183255B1 (en) 2000-03-27 2001-02-06 Yoshiki Oshida Titanium material implants
JP4955849B2 (ja) 2000-04-06 2012-06-20 健 八尾 アパタイト構造体、及びアパタイトパターン形成方法
WO2001076525A2 (en) 2000-04-10 2001-10-18 Advanced Cardiovascular Systems, Inc. Selectively coated stent delivery system and method of manufacture thereof
WO2001087371A2 (en) 2000-05-12 2001-11-22 Advanced Bio Prosthetic Surfaces, Ltd. Self-supporting laminated films, structural materials and medical devices
DE60124772T2 (de) 2000-05-19 2007-09-13 Advanced Bio Prothestic Surfaces, Ltd., San Antonio Verfahren und vorrichtung zur herstellung eines intravaskulären stents
US8632583B2 (en) * 2011-05-09 2014-01-21 Palmaz Scientific, Inc. Implantable medical device having enhanced endothelial migration features and methods of making the same
US6652579B1 (en) 2000-06-22 2003-11-25 Advanced Cardiovascular Systems, Inc. Radiopaque stent
JP2002017847A (ja) 2000-07-03 2002-01-22 Kikuji Yamashita 細胞外マトリックス結合型生体融和材料およびその製造方法、細胞外マトリックス製剤およびその製造方法
US6569194B1 (en) 2000-12-28 2003-05-27 Advanced Cardiovascular Systems, Inc. Thermoelastic and superelastic Ni-Ti-W alloy
JP3598973B2 (ja) 2001-01-10 2004-12-08 ソニー株式会社 利得可変回路
US6767360B1 (en) * 2001-02-08 2004-07-27 Inflow Dynamics Inc. Vascular stent with composite structure for magnetic reasonance imaging capabilities
DE60104647T2 (de) 2001-03-27 2005-08-11 William Cook Europe Aps Gefässtransplantat für die Aorta
US6527938B2 (en) 2001-06-21 2003-03-04 Syntheon, Llc Method for microporous surface modification of implantable metallic medical articles
US6444318B1 (en) 2001-07-17 2002-09-03 Surmodics, Inc. Self assembling monolayer compositions
US6746890B2 (en) 2002-07-17 2004-06-08 Tini Alloy Company Three dimensional thin film devices and methods of fabrication
CA2499976C (en) * 2002-09-26 2013-06-11 Advanced Bio Prosthetic Surfaces, Ltd. Implantable materials having engineered surfaces and method of making same
US8679517B2 (en) * 2002-09-26 2014-03-25 Palmaz Scientific, Inc. Implantable materials having engineered surfaces made by vacuum deposition and method of making same
US8268340B2 (en) 2002-09-26 2012-09-18 Advanced Bio Prosthetic Surfaces, Ltd. Implantable materials having engineered surfaces and method of making same
US8715771B2 (en) 2003-02-26 2014-05-06 Abbott Cardiovascular Systems Inc. Coated stent and method of making the same
US8281737B2 (en) 2003-03-10 2012-10-09 Boston Scientific Scimed, Inc. Coated medical device and method for manufacturing the same
DE602004024053D1 (de) 2003-05-07 2009-12-24 Advanced Bio Prothestic Surfac Metallische implantierbare prothesen und herstellungsverfahren dafür
US20050055085A1 (en) 2003-09-04 2005-03-10 Rivron Nicolas C. Implantable medical devices having recesses
US7296998B2 (en) 2003-09-22 2007-11-20 Bartee Chaddick M Hydrophilic high density PTFE medical barrier
US20050119723A1 (en) 2003-11-28 2005-06-02 Medlogics Device Corporation Medical device with porous surface containing bioerodable bioactive composites and related methods
US8715340B2 (en) 2004-03-31 2014-05-06 Merlin Md Pte Ltd. Endovascular device with membrane
CN101193666A (zh) * 2005-04-26 2008-06-04 奥胡斯大学 用于外科植入和引导细胞之组织培养表面的生物相容性材料
US20080299337A1 (en) * 2006-02-09 2008-12-04 Isoflux, Inc. Method for the formation of surfaces on the inside of medical devices
WO2007108373A1 (ja) 2006-03-17 2007-09-27 Kinki University 生体親和性透明シート、その製造方法、及び細胞シート
US8110242B2 (en) 2006-03-24 2012-02-07 Zimmer, Inc. Methods of preparing hydrogel coatings
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US7753962B2 (en) 2007-01-30 2010-07-13 Medtronic Vascular, Inc. Textured medical devices
JP5461202B2 (ja) * 2007-03-09 2014-04-02 アイコン メディカル コーポレーション 医療用具用生体吸収性コーティング
WO2009015420A1 (en) * 2007-07-27 2009-02-05 The University Of Sydney Biological functionalisation of substrates
DE102009023371A1 (de) 2009-05-29 2010-12-02 Acandis Gmbh & Co. Kg Verfahren zur Herstellung eines medizinischen Funktionselements mit einer freitragenden Gitterstruktur
US9186267B2 (en) 2012-10-31 2015-11-17 Covidien Lp Wing bifurcation reconstruction device
US20140128901A1 (en) 2012-11-05 2014-05-08 Kevin Kang Implant for aneurysm treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None
See also references of EP2707044A4

Also Published As

Publication number Publication date
US10729824B2 (en) 2020-08-04
MX2013013139A (es) 2014-05-27
CA2835844C (en) 2023-11-07
US20140294910A1 (en) 2014-10-02
CN103619364A (zh) 2014-03-05
CA2835844A1 (en) 2012-11-22
US20110274737A1 (en) 2011-11-10
AU2012255972A1 (en) 2014-01-16
US20190038815A1 (en) 2019-02-07
EP2707044B1 (en) 2025-06-04
US10039866B2 (en) 2018-08-07
EP2707044A2 (en) 2014-03-19
WO2012158614A3 (en) 2013-01-10
US8679517B2 (en) 2014-03-25
EP2707044C0 (en) 2025-06-04
US20170028109A1 (en) 2017-02-02
JP2014514127A (ja) 2014-06-19
AU2012255972B2 (en) 2016-06-23
EP2707044A4 (en) 2014-10-29
US9272077B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
CA2835844C (en) Implantable materials having engineered surfaces and method of making same
US10682443B2 (en) Implantable biomaterials having functional surfaces
Variola et al. Improving biocompatibility of implantable metals by nanoscale modification of surfaces: an overview of strategies, fabrication methods, and challenges
EP2706952B1 (en) Implantable medical device having enhanced endothelial migration features and methods of making the same
Fox et al. Surface modification of medical devices at nanoscale—Recent development and translational perspectives
JP2011502579A (ja) 多孔質貯蔵部および非ポリマー拡散層を備えた内部人工器官
KR101666672B1 (ko) 선택적 플라즈마 에칭을 이용하여 표면에 중금속 함유 나노구조물이 형성된 합금 기재의 제조방법 및 이의 용도

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/013139

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2835844

Country of ref document: CA

Ref document number: 2014510536

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012786428

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012255972

Country of ref document: AU

Date of ref document: 20120514

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 2012786428

Country of ref document: EP